Intermittent vascular claudication

Summary

Intermittent vascular claudication (MONDO:0005295) is a disease. A subtype of arteriosclerosis disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	intermittent vascular claudication
Mondo ID	MONDO:0005295
EFO	EFO:0003876
MeSH	D007383
DOID	DOID:3669
SNOMED CT	63491006
UMLS	C0021775
MedGen	7115
Is cancer (heuristic)	no

Disease family

This is a subtype of arteriosclerosis disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › arterial disorder › arteriosclerosis disorder › intermittent vascular claudication

Related subtypes (4): intracranial arteriosclerosis, Monckeberg arteriosclerosis, atherosclerosis, arteriosclerotic retinopathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 6 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Caffeine	Phase 3 (in late-stage trials)
Lovastatin	Phase 3 (in late-stage trials)
Metformin	Phase 3 (in late-stage trials)
Niacin	Phase 3 (in late-stage trials)
OMEGA-3-ACID ETHYL ESTERS	Phase 3 (in late-stage trials)
Rifalazil	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Cilostazol, Clopidogrel, Emiplacel, L-Citrulline, Simvastatin, Tirasemtiv, Zibotentan.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.